3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Gastrointestinal
5
Thoracic
2
Genitourinary
2
Sarcoma
1
Head & Neck
1
CNS
1
Breast
1
Conditions
Head and Neck Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
8
Nasopharyngeal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Salivary Gland Neoplasms
2
Recurrence
2
Osteosarcoma
2
Optic Nerve Glioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasm Metastasis
2
Melanoma
2
Familial ependymoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Astrocytoma
2
Wilms Tumor
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Spinocerebellar Degenerations
1
Interventions
pembrolizumab
19
Paclitaxel
6
Trastuzumab
5
Nivolumab
5
palbociclib
4
Carboplatin
4
Biopsy
4
lenvatinib
3
Taxes
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Immunoglobulin G
3
Fulvestrant
3
Cyclophosphamide
3
Cetuximab
3
trastuzumab deruxtecan
2
tisotumab vedotin
2
spartalizumab
2
sargramostim
2
gedatolisib
2
fludarabine
2
epacadostat
2
capivasertib
2
X-Rays
2
Sunitinib
2
Docetaxel
2
Disulfides
2
Cisplatin
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Oxaliplatin
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled